Alisporivir
As of the edition of 20 October 2026, Alisporivir is a protein: stopped in 2013; acts on PPIA.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Protein
- Registered trials
- 14, 2 stopped early
- Disease areas
- Digestive system; Infections; Blood and lymph; Cancer; Immune system; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Alisporivir.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPIA | Peptidyl-prolyl cis-trans isomerase A | P62937 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 2 | 0 | 0 |
| Phase 1 | 3 | 3 | 0 | 0 |
| Phase 2 | 5 | 5 | 0 | 0 |
| Phase 3 | 4 | 2 | 0 | 2 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Debiopharm | Lead sponsor of trials | 2007 to now |
| Enanta Pharmaceuticals | Lead sponsor of trials | 2014 to now |